A Multicentre, National, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
Phase of Trial: Phase III
Latest Information Update: 28 May 2016
At a glance
- Drugs Gemigliptin (Primary) ; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 17 May 2016 Status changed from active, no longer recruiting to completed.
- 04 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
- 04 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.